Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Warner Chilcott Company, a subsidiary of Warner Chilcott, has entered into an agreement with NexMed, a pharmaceutical and medical technology company, to acquire the US rights of NexMed's topically applied alprostadil cream for the treatment of erectile dysfunction.
Subscribe to our email newsletter
As a result, the previous licensing agreement between Warner Chilcott and NexMed related to this product has been terminated.
Under the terms of the agreement, NexMed received an up-front payment of $2.5 million and is eligible to receive an additional payment of $2.5 million upon Warner Chilcott’s receipt of a new drug application approval from the FDA. In addition, Warner Chilcott will pay a total of $350,000 for the manufacturing equipment for the product.